Cite
Hauswald H, Jensen AD, Krauss J, et al. Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynx. Clin Transl Radiat Oncol. 2018;13:64-73doi: 10.1016/j.ctro.2018.09.005.
Hauswald, H., Jensen, A. D., Krauss, J., Haselmann, R., Lossner, K., Hartmann, S., Windemuth-Kieselbach, C., Münter, M. W., & Debus, J. (2018). Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynx. Clinical and translational radiation oncology, 1364-73. https://doi.org/10.1016/j.ctro.2018.09.005
Hauswald, H, et al. "Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynx." Clinical and translational radiation oncology vol. 13 (2018): 64-73. doi: https://doi.org/10.1016/j.ctro.2018.09.005
Hauswald H, Jensen AD, Krauss J, Haselmann R, Lossner K, Hartmann S, Windemuth-Kieselbach C, Münter MW, Debus J. Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynx. Clin Transl Radiat Oncol. 2018 Sep 21;13:64-73. doi: 10.1016/j.ctro.2018.09.005. eCollection 2018 Nov. PMID: 30370340; PMCID: PMC6199783.
Copy
Download .nbib